3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Phase 1
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Lymphoma, Large B-Cell, Diffuse
13
Lymphoma
13
Prostatic Neoplasms
9
Precursor Cell Lymphoblastic Leukemia-Lymphoma
7
Hodgkin Disease
5
Leukemia
4
Neoplasms
3
Neoplasm Metastasis
3
Lymphoma, Non-Hodgkin
3
Leukemia, Biphenotypic, Acute
3
Burkitt Lymphoma
3
Breast Neoplasms
3
Recurrence
2
Ovarian Neoplasms
2
Lymphoma, Follicular
2
Lymphoma, B-Cell
2
Immunoblastic Lymphadenopathy
2
Hemangioma
2
Enteropathy-Associated T-Cell Lymphoma
2
Stomatitis
1
Stomach Neoplasms
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Philadelphia Chromosome
1
Peripheral Nervous System Diseases
1
Oral Ulcer
1
Neurotoxicity Syndromes
1
Neoadjuvant Therapy
1
Multiple Myeloma
1
Metastatic Castration-resistant Prostate Cancer
1
Metastatic Castration-Resistant Prostate Cancer Patients
1
Interventions
Cyclophosphamide
17
Etoposide
10
fludarabine
9
Whole-Body Irradiation
9
Brentuximab Vedotin
9
Melphalan
8
fludarabine phosphate
7
Vincristine
7
Mycophenolic Acid
7
Gemcitabine
7
Doxorubicin
7
Prednisone
6
Granulocyte Colony-Stimulating Factor
6
Busulfan
6
Vorinostat
5
Rituximab
5
Peripheral Blood Stem Cell Transplantation
5
Lenalidomide
5
Filgrastim
5
Cytarabine
5
Bortezomib
5
romidepsin
4
pembrolizumab
4
duvelisib
4
Tacrolimus
4
Stem Cell Transplantation
4
Carmustine
4
etoposide phosphate
3
Sirolimus
3
Dexamethasone
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Lymphoma, T-Cell
×
Prednisolone
×
Clear all
NCT01719835
2018-03-15
CHEMO-T
Royal Marsden NHS Foundation Trust
Phase 2
Unknown
87 enrolled